Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 8/20 | 0.63 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.63 |
| ▸ | PDE4A | P27815 | 4/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 4/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | PDE1A | P54750 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7864447 | 0.90 | PDE4B (0.74) | PDE4BPDE4CPDE4DPDE4APOLB | |
| SCHEMBL13460289 | 0.85 | PDE4B (0.82) | PDE4BPDE4CPDE4DPDE4ACHRM1 | |
| SCHEMBL12446525 | 0.78 | PDE4A (0.56) | PDE4BPDE4CPDE4DPDE4A | |
| SCHEMBL15012244 | 0.78 | PDE4B (0.71) | PDE4BPDE4CPDE4DPDE4APOLB | |
| SCHEMBL595613 | 0.78 | PDE4B (1.00) | PDE4BPDE4CPDE4DPDE4ACHRM1 | |
| SCHEMBL12446526 | 0.78 | ROCK2 (0.46) | PDE4BPDE4CPDE4DPDE4A | |
| SCHEMBL5583343 | 0.78 | PDE4B (1.00) | PDE4BPDE4CPDE4DPDE4ACHRM1 | |
| SCHEMBL10186869 | 0.76 | PDE4B (0.55) | PDE4BPDE4CPDE4DPDE4ACHRM1 | |
| SCHEMBL10186868 | 0.76 | PDE4B (0.55) | PDE4BPDE4CPDE4DPDE4AAR | |
| SCHEMBL10186836 | 0.76 | PDE4B (0.55) | PDE4BPDE4CPDE4DPDE4AAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461336-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8168614-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20110166104-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166104-A1 | BORON-CONTAINING SMALL MOLECULES | NFKBIA, BCL6B, TNF | PDE4B 543/4885PDE4C 1267/4885PDE4D 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.